A diverse pipeline of topical skin medications
EPSOLAY®Benzoyl Peroxide Cream, 5% Inflammatory Lesions of Rosacea | research | preclinical | phaseⅠⅠ | phaseⅠⅠⅠ | NDA submission | FDA Approved | Galderma Partnership |
TWYNEO®Tretinoin and Benzoyl Peroxide Cream, 0.1%/3% Acne Vulgaris | research | preclinical | phaseⅠⅠ | phaseⅠⅠⅠ | NDA submission | FDA Approved | Galderma Partnership |
SGT-210Topical Erlotinib Keratoderma & Other Dermatologic Indications | research | preclinical | phaseⅠⅠ | phaseⅠⅠⅠ | NDA submission | FDA Approved | |
SGT-310Tapinarof Cream Psoriasis & Other Dermatologic Indications | research | preclinical | phaseⅠⅠ | phaseⅠⅠⅠ | NDA submission | FDA Approved | |
SGT-510Topical Roflumilast + “Agent A Psoriasis & Other Dermatologic Indications | research | preclinical | phaseⅠⅠ | phaseⅠⅠⅠ | NDA submission | FDA Approved |
Our Microencapsulation Technology
EPSOLAY®
EPSOLAY is a topical cream containing benzoyl peroxide, 5%, FDA approved for the treatment of inflammatory lesions of rosacea in adults. EPSOLAY utilizes proprietary technology in order to encapsulate benzoyl peroxide within silica-based microcapsules to create a barrier between the medication and the skin. The silica-based shell is designed to slowly release benzoyl peroxide over time to provide a favorable efficacy and safety profile. EPSOLAY is protected by granted patents until 2040.
*Not an actual patient – actor portrayal
*Not an actual patient – actor portrayal
EPSOLAY®
EPSOLAY is an investigational topical cream containing benzoyl peroxide, 5%, under FDA review for the treatment of inflammatory lesions of rosacea in adults. EPSOLAY utilizes proprietary technology in order to encapsulate benzoyl peroxide within silica-based microcapsules to create a barrier between the medication and the skin. The silica-based shell is designed to slowly release benzoyl peroxide over time to provide a favorable efficacy and safety profile. EPSOLAY is protected by granted patents until 2040. The FDA is expected to conduct a pre-approval inspection of the production site for EPSOLAY during the week of February 14th, 2022.
The safety and efficacy of Epsolay have not been established.
Epsolay is a registered trademark of Sol-Gel Technologies, Ltd.
*Not an actual patient – actor portrayal
TWYNEO®
TWYNEO is a topical cream containing a fixed-dose combination of tretinoin and benzoyl peroxide, 0.1%/3%, for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older. Tretinoin and benzoyl peroxide have a complementary mechanism of action and are widely prescribed separately for acne vulgaris; however, no combination of the two, other than TWYNEO, has been approved by the FDA because benzoyl peroxide decomposes tretinoin rapidly – so patients cannot use both drugs concomitantly. TWYNEO utilizes a proprietary technology to encapsulate both benzoyl peroxide and tretinoin within silica-based microcapsules to prevent the decomposition of tretinoin by benzoyl peroxide and to reduce the irritation associated with both active substances. TWYNEO is protected by granted patents until 2038.
SGT-210
SGT-210 is an investigational innovative topical erlotinib drug candidate for the treatment of keratoderma and other skin conditions. Erlotinib is a tyrosine kinase receptor inhibitor which acts on the EGFR. A proof-of-concept clinical study we conducted in palmoplantar keratoderma patients indicated a potential modest improvement with a favorable safety profile. We plan to initiate the clinical development of SGT-210, with a higher concentration of erlotinib.
SGT-310
SGT-310 is an innovative tapinarof cream drug candidate for the treatment of psoriasis and other skin conditions intended to be an alternative to a tapinarof cream, 1%, for which an NDA was already submitted to the FDA. Tapinarof is an aryl hydrocarbon receptor modulating agent. We are aiming develop SGT-310 without relying on any listed drug, such that we will not be subject to Hatch-Waxman 30-month stay.
SGT-510
SGT-510 is a proprietary topical roflumilast drug candidate designed to be potentially more effective than a roflumilast cream, 0.3%, for which an NDA was already submitted to the FDA. Roflumilast is a selective inhibitor of PDE4.